

Industrial Practices for Determining Biopharm Products' Critical Quality Attributes (CQAs).

Wasfi AlAzzam

PhD, Chief Scientific Officer, TechnoPharmaSphere LLC

Abstract

Analytical methods have been playing a major role in creating in vitro and in vivo product characterization packages. Compiling both sets of data helps in-depth understanding of product's quality attributes (QA) and helps in the determination of product's CQAs. It is proven that some CQAs have impact on the product's safety and biological profiles. Biopharm industry is now revising their testing strategies to accelerate product development. This talk will connect analytical, CQAs, and clinical outcomes in product's development

Biograph :

Wasfi AlAzzam PhD, Chief Scientific Officer, TechnoPharmaSphere LLC

References :

1. Stockdale, Gregory & Murphy, Brian & D'Antonio, Jennifer & Manning, Mark & Alazzam, Wasfi. (2015). Comparability of Higher Order Structure in Proteins: Chemometric Analysis of Second-Derivative Amide I Fourier Transform Infrared Spectra. *Journal of Pharmaceutical Sciences*. 104. 10.1002/jps.24218.
2. D'antonio, Jennifer & Murphy, Brian & Manning, Mark & Al-Azzam, Wasfi. (2012). Comparability of Protein Therapeutics: Quantitative Comparison of Second-Derivative Amide I Infrared Spectra. *Journal of pharmaceutical sciences*. 101. 2025-33. 10.1002/jps.23133.
3. Castillo, Betzaida & Pacheco, Yamaris & Al-Azzam, Wasfi & Griebenow, Kai & Devi, Manjula & Ferrer, Amaris & Barletta, Gabriel. (2005). On the activity loss of hydrolases in organic solvents: I. Rapid loss of activity of a variety of enzymes and formulations in a range of organic solvents. *Journal of Molecular Catalysis B: Enzymatic*. 35. 147–153. 10.1016/j.molcatb.2005.06.008.

Citation Wasfi AlAzzam PhD, Industrial Practices for Determining Biopharm Products' Critical Quality Attributes (CQAs); *Pharmacology* 2021; April 30, 2021; London, UK